망막중심정맥폐쇄에 동반된 황반부종에서 라니비주맙 주입술의 단기 임상 효과

• 영문명: The Short-Term Efficacy of Intravitreal Ranibizumab for Macular Edema in Central Retinal Vein Occlusion
• 발행기관: 대한안과학회
• 저자명: 신혜영 지동현,Hye Young Shin, MD, Dong Hyun Jee, MD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume52,number9, 1048~1054쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2011.09.15

영문 초록

Purpose: To evaluate the short-term efficacy of intravitreal ranibizumab injection in eyes with macular edema secondary to central retinal vein occlusion (CRVO). Methods: The records of 17 patients (17 eyes, 11 ischemic, six ischemic) who received an intravitreal ranibizumab injection for macular edema secondary to CRVO were retrospectively analyzed. The ophthalmic examination included best corrected visual acuity (BCVA) and central macular thickness (CMT) at baseline and follow-up visits. Results: After intravitreal ranibizumab injection, the mean BCVA improved from log MAR 1.25 ± 0.47 at baseline to log MAR 0.78 ± 0.49 at 4 weeks and to log MAR 0.81 ± 0.52 at 12 weeks (p < 0.05). Additionally, the mean CMT decreased from 679.4 ± 230.5 μm at baseline to 224.4 ± 129.9 μm at 4 weeks and to 271.6 ± 174.1 μm at 12 weeks (p < 0.001). In subgroup analysis, the decreases in CMT at 4 weeks and 12 weeks were similar in ischemic CRVO and non-ischemic CRVO, but no significant changes in visual acuity were found at 12 weeks in the ischemic CRVO group (p = 0.138). Ten eyes (58.8%) did not require re-injections for macular edema for up to 12 weeks. Conclusions: Intravitreal ranibizumab injection appeared to be an effective option for the treatment of macular edema secondary to central retinal vein occlusion. J Korean Ophthalmol Soc 2011;52(9):1048-1054

키워드

Central retinal vein occlusion, Macular edema, Ranibizumab